Breadcrumb Home Business activities ΒιΆΉΤΌΕΔ BioCapital ΒιΆΉΤΌΕΔ Biocapital Portfolio Celladon Celladon Was in phase II/III trial with a SERCa2a gene therapy to help heart failure patients hearts to beat without increasing their oxygen consumption. ΒιΆΉΤΌΕΔ BioCapital Invested 2010 IPO in 2013 β CLDN (Nasdaq) Location La Jolla, California, USA
